BIA celebrates RQ BIO licencing agreement with AstraZeneca for monoclonal antibodies targeted at COVID-19

Today RQ BIO has announced a licencing agreement with AstraZeneca for its portfolio of early-stage monoclonal antibodies targeted against SARS-CoV-2, with the company also emerging from stealth mode on completion of the agreement. RQ Bio is a UK-based biotechnology company focused on developing treatments and preventative therapies based on potent broad-spectrum mAbs to address areas of unmet need in vulnerable patient populations.

Coulter Partners places Chief Operating Officer at Treadwell Therapeutics, playing an integral role in the company’s evolution

Coulter Partners, the global experts in Executive Search and Leadership Development in Life Sciences, Health, and Tech, recently partnered with Treadwell Therapeutics, a clinical-stage biotechnology company developing novel, cross-modality medicines for unmet needs in cancer, and are pleased to announce the placement of J.D. Mowery as Chief Operating Officer (COO).

CEO Update | 16 May 2022

Last week we gave our response to the Department of Work and Pensions consultation on facilitating investments in illiquid assets. We called on the UK Government to improve transparency in the pensions industry so that pension savers have access to diversified investment strategies benefiting from the wealth-creating opportunities of the UK’s innovative, venture capital-backed industries, including biotech and life sciences, while supporting issues the public care about, like better healthcare and a cleaner environment.

Innovation community at The Oxford Science Park expands further as companies move into the Hayakawa Building

The innovation community at The Oxford Science Park, one of Europe's leading locations for science and technology companies, continues to expand as firms move into the newly refurbished Hayakawa Building.

BioIVT to Provide Rare Biosamples for the FNIH Biomarkers Consortium Neurodegenerative Disease Project

BioIVT is sourcing matched sets of cerebrospinal fluid, serum, and plasma from donors afflicted with ALS to further research of neurofilament in the blood as a biomarker for early stages of neurodegeneration.

Coulter Partners announces two additional appointments in Italy

Coulter Partners announces two additional appointments to its new Milan office. Giulia Bacis joins as Senior Consultant and Anna Senzacqua as Consultant. Together with Francesca Lazzarin, Executive Director, Yasemin Holland, Senior Research Associate and Giuliana Milioto, Research Associate, they make up the Italian team who will enrich the firm’s offering to companies growing from Italian headquarters and those expanding into Italy.

Human Strategy Series – Michael Huberts, Executive Director, at Coulter Partners, provides an Australian Perspective on Executive Search and Leadership Consulting

Michael Huberts, Executive Director at Coulter Partners, provides an Australian perspective on Executive Search and Leadership Consulting in the Life Sciences, Health and Tech sectors. He explores the impact of the global Covid pandemic, the challenges of shrinking talent pools, government initiatives and investments, leadership diversity, digital health, and current trends.

Give pension savers the opportunity to invest in the development of new medicines and a greener economy

The BioIndustry Association (BIA) has called on the UK Government to improve transparency in the pensions industry so that savers can make informed decisions on what their money is invested in.

PrecisionLife and Sano Genetics announce partnership to accelerate understanding of long COVID and help identify new treatments

A new partnership between PrecisionLife and Sano Genetics will help advance researchers’ understanding of the drivers of long COVID, identifying at-risk patients and potential drug targets.

CEO Update | 9 May 2022

Congratulations to Omass Therapeutics for raising $100 million in the Series B financing round, as well as two BIA member companies - Scotland-based EnteroBiotix and Solvemed group, who were featured in Forbes ‘30 under 30 Europe’ Science and Healthcare Edition for 2022. We are also glad to see engineering biology receive £20.6 million in investment from UK Research and Innovation (UKRI). Read more on IP TRIPS Waiver, update on Northern Ireland and BBSRC Business and Academia Prosperity Partnership.